Repare Therapeutics
7210 Frederick-Banting
Suite 100
St-Laurent
Quebec
H4S 2A1
Canada
Website: http://www.reparerx.com/
Email: info@reparerx.com
About Repare Therapeutics
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics. The company is backed by leading global healthcare investors including founding investor Versant Ventures and MPM Capital.YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Daniel Durocher, PhD., Frank Sicheri, PhD and Agnel Sfeir, PhD
President & CEO: Lloyd M. Segal
EVP, Business & Corporate Development: Kim Seth
VP, Discovery: Cameron Black
EVP, Head of R&D: Michael Zinda
CAREER:
Please click here for Repare Therapeutics' job opportunities.
92 articles about Repare Therapeutics
-
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
6/6/2023
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.
-
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
6/2/2023
Repare Therapeutics Inc. today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time.
-
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/22/2023
Repare Therapeutics Inc. today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’s common shares.
-
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
5/9/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023.
-
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
4/28/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2023.
-
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
4/18/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche).
-
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
3/14/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida.
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences - February 2, 2023
2/2/2023
Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in February and March.
-
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
1/19/2023
Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).
-
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans - December 19, 2022
12/19/2022
Repare Therapeutics Inc. today announced that they have established new Automatic Securities Disposition Plans (“ASDPs”), or in the case of Maria Koehler modified her existing ASDP, in accordance with applicable United States and Canadian securities legislation.
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/9/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
11/7/2022
Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in November.
-
Repare Therapeutics to Participate in Two Upcoming September 2022 Investor Conferences
9/7/2022
Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced that members of its senior management team will participate at two investor conferences in September.
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8/4/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.
-
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
6/7/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.
-
Versant Ventures to File Early Warning Report in Respect of Repare Therapeutics Inc.
6/6/2022
Versant Ventures today announced it will file an early warning report with respect to the ownership of securities in Repare Therapeutics Inc.
-
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
-
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
6/1/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500).
-
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
5/9/2022
Repare Therapeutics Inc. announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.